@article{article, title  = {{Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2022}},

 month = {{4}},

 author = {{Nanchahal J and Ball C and Rombach I and Williams L and Kenealy N and Dakin H and O'Connor H and Davidson D and Werker P and Dutton SJ and Feldmann M et al}},

 doi = {{10.1016/s2665-9913(22)00093-5}},

 volume = {{4}},

 journal = {{The Lancet Rheumatology}},

 issue = {{6}},

 pages = {{E407-E416}},

 note = {{Accessed on 2024/12/22}}}